Figure 5
![Figure 5. PARP1 inhibition decreases ZFN-mediated translocations in cells of hematopoietic origin. Jurkat cells were treated with olaparib or rucaparib, and translocations induced by ZFN pairs were measured by assaying der[3] formation by using semiquantitative PCR at the indicated times, as shown in Figure 4.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/121/21/10.1182_blood-2012-10-460527/4/4359f5.jpeg?Expires=1724956810&Signature=3PuU9B1OMyxzkQVZGrMQ3Xdk8brS7DG~3NcWzNXr7fvpWHO7NjLYYZ3CuZ9Jt2SIpTouALTsMNVcCcWma2HOEV1AzOJ0oxQXGXAjM~~TGjIQ-vKc9HyhSKIyswGWUP0MIt7Z-6V5FwV~nkl7duUeSrIJrOmxj3N9EPqeCSSSMvKNMdjW1hA0bxyGd4aWfADWlrvLKsaCFu3sVst9WXGT65wVFRs0AbhWhPDbpEp0CkU02CizU-uBfboqbyNLNGi434sbPki7cukIzwPhHhsVAT~kwoW~~TDa7B5GK7~l6XD8MVKlvx8glGtMO1pZRwEwCpeAOyKUeGlqvNR6bIh8~Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PARP1 inhibition decreases ZFN-mediated translocations in cells of hematopoietic origin. Jurkat cells were treated with olaparib or rucaparib, and translocations induced by ZFN pairs were measured by assaying der[3] formation by using semiquantitative PCR at the indicated times, as shown in Figure 4.
